BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, November 22, 2024
See today's BioWorld
Home
» Zybrestat's Phase II Ovarian Cancer Trial Passes Review
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Zybrestat's Phase II Ovarian Cancer Trial Passes Review
Feb. 8, 2013
By
Catherine Shaffer
No Comments
Shares of OxiGene Inc. bounced 14.8 percent Thursday on news that its Phase II study of Zybrestat and Avastin in ovarian cancer demonstrated acceptable tolerability in an interim toxicity analysis.
BioWorld
